Volume 27, Issue 5 (10-2019)
JSSU 2019, 27(5): 1505-1515 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Akhondi-Meybodi M. New treatment of hepatitis C (Direct Acting Antiviral). JSSU 2019; 27 (5) :1505-1515
URL: http://jssu.ssu.ac.ir/article-1-4743-en.html
URL: http://jssu.ssu.ac.ir/article-1-4743-en.html
Abstract: (2903 Views)
Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with approximately 71 million chronically infected individuals worldwide. Clinical care for the patients with HCV-related liver disease has advanced considerably thanks to an enhanced understanding of the pathophysiology of the disease, and because of developments in diagnostic procedures and improvements in therapy and prevention, recently in Iran new drug direct Acting agent (DAA) was developed that may be equivalent to original drugs that will hope to treat HCV and eliminated HCV in future
Keywords: hepatitis c, DAA Direct Acting Antiviral.
Type of Study: Review article |
Subject:
Infectious Diseases
Received: 2018/11/17 | Accepted: 2019/01/19 | Published: 2019/10/9
Received: 2018/11/17 | Accepted: 2019/01/19 | Published: 2019/10/9
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
